Status | Study |
Not yet recruiting |
Study Name: Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians Condition: Lichen Amyloidosis Date: 2017-02-20 Interventions: Procedure: Methylene blue-mediated photodynamic therapy The 2% MB aqueous solution was applied to the le |
Recruiting |
Study Name: Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians Condition: Lichen Amyloidosis Date: 2017-02-20 Interventions: Radiation: 308-nm excimer laser monochromator UVB laser (308nm) |
Available |
Study Name: Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) Condition: TTR-mediated Amyloidosis Amyloidosis, Hereditary Amyloid N Date: 2016-10-18 Interventions: Drug: patisiran (ALN-TTR02) patisiran (ALN-TTR02) administered by intravenous (IV) infusion |
Completed |
Study Name: The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage? Condition: CADASIL Date: 2016-07-13 Interventions: Other: No intervention |
Recruiting |
Study Name: A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects Condition: Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) Date: 2016-05-18 Interventions: Drug: ALN-TTRSC02 Ascending do |
Recruiting |
Study Name: Carpal Tunnel Syndrome and Amyloid Cardiomyopathy Condition: Amyloidosis Cardiomyopathy Transthyretin Amyloidosis Date: 2016-04-20 |
Recruiting |
Study Name: Biomarker for Patients With Transthyretin-Related Familial Amyloidotic Polyneuropathy Condition: Metabolic Diseases Amyloid Neuropathies Date: 2016-01-13 |
Completed |
Study Name: The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant Condition: Transthyretin (TTR)-Mediated Amyloidosis Familial Amyloidotic Polyneuropathy (FAP) Date: 2015-10-30 Interventions: Drug: Revusiran (ALN-TTRSC) 500mg Revusiran by subcutaneous (sc) injection |
Active, not recruiting |
Study Name: Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy Condition: Cerebral Amyloid Angiopathy Intracerebral Hemorrhage Date: 2015-02-03 |
Completed |
Study Name: ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Condition: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Amyloidosis, Heredita Date: 2014-12-12 Interventions: Drug: Revusiran (ALN-TTRSC) Drug: Sterile |